OTCMKTS:RSPI

RespireRx Pharmaceuticals Competitors

$0.04
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.03
Now: $0.04
$0.05
50-Day Range
$0.03
MA: $0.05
$0.07
52-Week Range
$0.01
Now: $0.04
$0.26
Volume724,392 shs
Average Volume1.51 million shs
Market Capitalization$2.82 million
P/E RatioN/A
Dividend YieldN/A
Beta0.43

Competitors

RespireRx Pharmaceuticals (OTCMKTS:RSPI) Vs. PKPH, WHCA, ACUR, GBIM, ULUR, and NXEN

Should you be buying RSPI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to RespireRx Pharmaceuticals, including Peak Pharmaceuticals (PKPH), Williston (WHCA), Acura Pharmaceuticals (ACUR), GlobeImmune (GBIM), ULURU (ULUR), and Nexien BioPharma (NXEN).

RespireRx Pharmaceuticals (OTCMKTS:RSPI) and Peak Pharmaceuticals (OTCMKTS:PKPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Profitability

This table compares RespireRx Pharmaceuticals and Peak Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RespireRx PharmaceuticalsN/AN/A-3,387.16%
Peak PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for RespireRx Pharmaceuticals and Peak Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RespireRx Pharmaceuticals0000N/A
Peak Pharmaceuticals0000N/A

Volatility & Risk

RespireRx Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Peak Pharmaceuticals has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.

Valuation & Earnings

This table compares RespireRx Pharmaceuticals and Peak Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RespireRx PharmaceuticalsN/AN/A$-2,120,000.00N/AN/A
Peak PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Peak Pharmaceuticals beats RespireRx Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

RespireRx Pharmaceuticals (OTCMKTS:RSPI) and Williston (OTCMKTS:WHCA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Profitability

This table compares RespireRx Pharmaceuticals and Williston's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RespireRx PharmaceuticalsN/AN/A-3,387.16%
WillistonN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for RespireRx Pharmaceuticals and Williston, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RespireRx Pharmaceuticals0000N/A
Williston0000N/A

Volatility & Risk

RespireRx Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Williston has a beta of -1.09, meaning that its stock price is 209% less volatile than the S&P 500.

Valuation & Earnings

This table compares RespireRx Pharmaceuticals and Williston's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RespireRx PharmaceuticalsN/AN/A$-2,120,000.00N/AN/A
WillistonN/AN/AN/AN/AN/A

RespireRx Pharmaceuticals (OTCMKTS:RSPI) and Acura Pharmaceuticals (OTCMKTS:ACUR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares RespireRx Pharmaceuticals and Acura Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RespireRx PharmaceuticalsN/AN/A-3,387.16%
Acura Pharmaceuticals-19.89%-1.36%-34.83%

Volatility and Risk

RespireRx Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Acura Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for RespireRx Pharmaceuticals and Acura Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RespireRx Pharmaceuticals0000N/A
Acura Pharmaceuticals0000N/A

Earnings and Valuation

This table compares RespireRx Pharmaceuticals and Acura Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RespireRx PharmaceuticalsN/AN/A$-2,120,000.00N/AN/A
Acura Pharmaceuticals$2.66 million3.49N/AN/AN/A

Acura Pharmaceuticals has higher revenue and earnings than RespireRx Pharmaceuticals.

GlobeImmune (OTCMKTS:GBIM) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares GlobeImmune and RespireRx Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GlobeImmuneN/AN/AN/A
RespireRx PharmaceuticalsN/AN/A-3,387.16%

Valuation & Earnings

This table compares GlobeImmune and RespireRx Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlobeImmuneN/AN/AN/AN/AN/A
RespireRx PharmaceuticalsN/AN/A$-2,120,000.00N/AN/A

Analyst Ratings

This is a summary of current ratings and price targets for GlobeImmune and RespireRx Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GlobeImmune0000N/A
RespireRx Pharmaceuticals0000N/A

Volatility and Risk

GlobeImmune has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Comparatively, RespireRx Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Summary

GlobeImmune beats RespireRx Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

ULURU (OTCMKTS:ULUR) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for ULURU and RespireRx Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ULURU0000N/A
RespireRx Pharmaceuticals0000N/A

Profitability

This table compares ULURU and RespireRx Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ULURUN/AN/AN/A
RespireRx PharmaceuticalsN/AN/A-3,387.16%

Earnings and Valuation

This table compares ULURU and RespireRx Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ULURUN/AN/AN/AN/AN/A
RespireRx PharmaceuticalsN/AN/A$-2,120,000.00N/AN/A

Volatility & Risk

ULURU has a beta of -2.9, meaning that its share price is 390% less volatile than the S&P 500. Comparatively, RespireRx Pharmaceuticals has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

RespireRx Pharmaceuticals (OTCMKTS:RSPI) and Nexien BioPharma (OTCMKTS:NXEN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current recommendations for RespireRx Pharmaceuticals and Nexien BioPharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RespireRx Pharmaceuticals0000N/A
Nexien BioPharma0000N/A

Earnings & Valuation

This table compares RespireRx Pharmaceuticals and Nexien BioPharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RespireRx PharmaceuticalsN/AN/A$-2,120,000.00N/AN/A
Nexien BioPharmaN/AN/A$-2,670,000.00N/AN/A

Profitability

This table compares RespireRx Pharmaceuticals and Nexien BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RespireRx PharmaceuticalsN/AN/A-3,387.16%
Nexien BioPharmaN/A-16,049.80%-6,651.95%

Volatility and Risk

RespireRx Pharmaceuticals has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Nexien BioPharma has a beta of -701.47, meaning that its share price is 70,247% less volatile than the S&P 500.

Summary

RespireRx Pharmaceuticals beats Nexien BioPharma on 4 of the 4 factors compared between the two stocks.


RespireRx Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.13flat$10.33 millionN/A0.00Gap Up
Williston logo
WHCA
Williston
0.0$0.70flat$9.51 millionN/A0.00
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.42flat$9.28 million$2.66 million-14.00
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.55flat$8.91 millionN/A0.00
ULUR
ULURU
0.3$0.28flat$8.17 millionN/A0.00
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.13flat$7.33 millionN/A0.00Gap Up
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.36flat$7.20 millionN/A0.00
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.08flat$7.15 millionN/A0.00
KAYS
Kaya
0.7$0.44flat$6.35 million$1.01 million0.00Gap Up
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.05flat$5.71 million$30,000.000.00High Trading Volume
Gap Up
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.20flat$4.74 million$3.48 million-1.67
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00flat$4.56 millionN/A0.00Gap Down
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.54flat$4.07 million$9.47 million0.00High Trading Volume
Gap Up
Amarantus BioScience logo
AMBS
Amarantus BioScience
0.0$0.01flat$3.87 millionN/A0.00Increase in Short Interest
Gap Down
AKRXQ
Akorn
0.1$0.03flat$3.60 million$682.43 million-0.01
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.09flat$3.60 million$3.65 million0.00News Coverage
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01flat$3.50 millionN/A0.00Gap Up
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.14flat$2.88 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02flat$2.20 million$20,000.00-0.99Gap Up
IMUCD
ImmunoCellular Therapeutics
0.0$0.51flat$2.14 millionN/A0.00Gap Up
VVUSQ
VIVUS
0.6$0.12flat$2.10 million$69.76 million-0.04
NSPX
Inspyr Therapeutics
0.5$0.01flat$1.97 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01flat$1.95 million$2 million0.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.04flat$1.83 million$530,000.000.00
WWHC
W World
0.8$6.09flat$1.80 millionN/A0.00Increase in Short Interest
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.48flat$1.70 millionN/A0.00Gap Up
Cardax logo
CDXI
Cardax
0.0$2.00flat$1.59 million$710,000.000.00News Coverage
MLNTQ
Melinta Therapeutics
0.2$0.11flat$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$1.30 million$8.73 million0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.24flat$1.27 millionN/A0.00Decrease in Short Interest
Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.02flat$1.17 millionN/A0.00
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05flat$1.12 millionN/A-0.57Upcoming Earnings
High Trading Volume
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$1.07 millionN/A0.00Increase in Short Interest
Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04flat$978,000.00N/A0.00Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07flat$970,000.00N/A0.00Increase in Short Interest
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08flat$872,000.00$250,000.000.00
PXYN
Praxsyn
0.6$0.00flat$848,000.00N/A0.00Increase in Short Interest
News Coverage
SKVI
Skinvisible
0.7$0.15flat$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05flat$572,000.00$1.90 million0.00
SPHS
Sophiris Bio
0.1$0.02flat$567,000.00N/A0.00Increase in Short Interest
Gap Up
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.02flat$506,000.00N/A0.00Gap Up
TRPXD
Therapix Biosciences
0.0$9.00flat$450,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.15flat$396,000.00N/A0.00News Coverage
Gap Up
HSTC
HST Global
0.8$0.07flat$378,000.00N/A0.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01flat$343,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00Gap Up
PZRXQ
PhaseRx
0.2$0.02flat$298,000.00N/A0.00Gap Down
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01flat$244,000.00N/A0.00
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.